Incidence of Allergic Drug Eruption due to Cotrimoxazole in HIV-Positive Individuals with CD4 ≤200 Cells/ul - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36700255/
Allergic drug eruptions (ADE) remain a challenge in people living with HIV (PLWH), requiring more studies to guide clinical approaches. While cotrimoxazole is widely used as prophylaxis in PLWH, relationship...
Conclusion: Allergic drug eruptions due to cotrimoxazole or TMP/SMX is unrelated to CD4 level in 1789 people living with HIV presented with CD4 level 90%) in clients with ADEs. Age, gender, exposure risks, and comorbidities presented on ART initiation does not affect cotrimoxazole hypersensitivity in our study. While ADE severity ranges from...
Differences in drug resistance of HIV-1 genotypes in CSF and plasma and analysis of related factors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36694270/
The emergence of HIV drug resistance seriously affects the quality of life of patients. However, there has been no extensive study of CSF resistance. The aim of this study is...
Conclusions/Relevance: The type with the highest mutation frequency was NNRTI, and no mutation was found in INSTI. Multivariate analysis indicated that ARV treatment was associated with CSF resistance (P
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36680233/
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with...
Relevance/Conclusions: The study confirmed after 48 months from the 2DR-3TC-based switch in PLWH that HBcAb-positivity is associated with the worst HIV viremia control after 48 months of follow-up and less frequently maintains the persistent virological suppression during the entire follow-up. Moreover, we showed that HBcAb-positive PLWH has a...
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? - Current HIV/AIDS Reports
Source : https://link.springer.com/article/10.1007/s11904-023-00647-z
Purpose of Review HIV/AIDS and COVID-19 have been the major pandemics overwhelming our times. Given the enduring immune disfunction featuring people living with HIV (PLWH) despite combination antiretroviral therapy (cART),...
Summary: Scarce immunovirological control appears to be the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH. Therefore, such individuals should be prioritized for vaccination and should receive additional vaccine doses. Furthermore, given the potentially higher risk of developing...
Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study
Source : https://thorax.bmj.com/content/early/2023/01/13/thorax-2022-218910
Introduction Chronic lung disease is common among people living with HIV (PLWH). We hypothesised that PLWH receiving antiretroviral therapy (ART) have faster lung function decline than matched controls.
Conclusion: Well-treated PLWH have faster lung function decline than controls and smoking seems to modify this association, suggesting that smoking may lead to more rapid lung function decline in PLWH than in controls.